¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"plasma histaminase activity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • molar activity
    ¸ôȰ¼º
  • mental activity
    Á¤½ÅȰµ¿
  • psychomotor activity
    Á¤½Å¿îµ¿È°µ¿
  • partial agonistic activity
    ºÎºÐÀÛ¿ëÁ¦È°¼º
  • specific activity
    1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
  • spontaneous activity
    ÀÚ¹ßÀüÀ§
  • structure activity relationship
    ±¸Á¶È°¼º»ó°ü°ü°è, ±¸Á¶ÀÛ¿ë°ü°è
  • sexual activity
    ¼ºÈ°µ¿
  • antihemophilic human plasma
    Ç×Ç÷¿ìº´Ç÷Àå
  • blood plasma
    Ç÷Àå
  • effective renal plasma flow
    À¯È¿ÄáÆÏÇ÷ÀåÀ¯·®, À¯È¿½ÅÀåÇ÷ÀåÀ¯·®
  • fresh frozen plasma
    ½Å¼±³Ãµ¿Ç÷Àå
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
  • normal human plasma
    Á¤»ó»ç¶÷Ç÷Àå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mental activity
    Á¤½ÅȰµ¿
  • molar activity
    ¸ôȰ¼º
  • partial agonistic activity
    ºÎºÐÈ¿´ÉȰ¼º
  • psychomotor activity
    Á¤½Å¿îµ¿È°µ¿
  • reflex gamma activity
    ¹Ý»ç°¨¸¶È°µ¿
  • sexual activity
    ¼ºÈ°µ¿
  • specific activity
    ºñ¹æ»ç´É, ƯÀÌȰ¼ºµµ
  • spontaneous activity
    ÀÚ¹ßÀüÀ§
  • time-activity curve
    ½Ã°£¹æ»ç´É°î¼±
  • professional activity study
    Àü¹®°¡È°µ¿¿¬±¸
  • structure activity relationship
    ±¸Á¶È°¼º»ó°ü°ü°è, ±¸Á¶ÀÛ¿ë°ü°è
  • sperm activity grade test
    Á¤Àڿµî±Þ°Ë»ç
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå
  • blood plasma
    Ç÷Àå
  • plasma cell
    ÇüÁú¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemolytic activity
    ¿ëÇ÷´É
  • homosexual activity
    µ¿¼º¾ÖÀû ÇàÀ§
  • psychomotor activity
    Á¤½Å¿îµ¿¼º Ȱµ¿.
  • realtive sepcific activity
    »ó´ëºñ¹æ»ç´É
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • ERPF=£¾effective renal plasma flow
    À¯È¿½ÅÇ÷·ù·®.
  • RPF => renal plasma flow
    ½ÅÇ÷Àå·ù(·®)
  • RPR test => rapid plasma reagin test
    ½Å¼ÓÇ÷À帮¾ÆÁø<°¨ÀÛÇ×ü>½ÃÇè
  • TPC=£¾thromboplastin plasma component
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾Ç÷À强ºÐ.
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (¡­úìíì).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (?Ì´Ëö).
  • fresh frozen plasma=FFP
    ½Å¼±µ¿°áÇ÷Àå
  • plasma
    Ç÷Àå(úìíì), ÇöóÁ.
  • plasma
    Ç÷Àå
  • plasma analysis
    Ç÷ÀåºÐ¼®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • displacement activity
    ÀüġȰµ¿
  • effect concentration(=activity)
    À¯È¿³óµµ(êóüùÒØÓø)
  • elastolytic activity
    ¿¤¶ó½ºÆ¾¿ëÇØÈ°¼º(µµ), ¿¤¶ó½ºÅ¸¾ÆÁ¦È°¼º(µµ).
  • enzyme activity
    È¿¼ÒȰ¼º
  • enzyme activity
    È¿¼ÒȰ¼ºµµ
  • epidemiologic activity
    ¿ªÇÐÀû Ȱµ¿(ËçÌ°Ëø Ì·ËÄ).
  • fibrinolytic activity
    ¼¶À¯¼Ò¿ëÇØ´É
  • functional activity
    ±â´É¼º Ȱ¼ºµµ<Ȱµ¿µµ>
  • fusion activity
    À¶ÇÕ´É
  • glucagon activity
    ±Û·çÄ«°ïȰ¼ºµµ.
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hemolytic activity
    ¿ëÇ÷´É
  • homosexual activity
    µ¿¼º¾ÖÀû ÇàÀ§
  • insulin like activity =ILa
    Àν¶¸°¾çȰ¼º(ÀÛ¿ë).
  • insulin-like activity substance
    Àν¶¸°¾çȰ¼º¹°Áú.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • specific activity
    ºñȰ¼º(ÝïüÀàõ)
  • suppressible insulin-like activity
    ¾ï¾Ð °¡´É(åääâʦÒö) Àν¶¸°À¯»çȰ¼º(×¾ÞÄüÀàõ)
  • surface activity
    Ç¥¸éȰ¼º (øúØüüÀàõ)
  • vibrational optical activity
    Áøµ¿ ±¤ÇРȰ¼º(òÉÔÑÎÃùÊ üÀàõ)
  • blood plasma
    Ç÷Àå(úìíì)
  • native plasma
    ÀÚ¿¬(í»æÔ) Çö󽺸¶
  • plasma
    "Ç÷Àå(úìíì), ÇöóÁ"
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà)
  • plasma clearance
    Ç÷ÀåûÁ¤(úìíìôèïä)
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­)
  • plasma gel
    Á©»ó(ßÓ) ¿øÇüÁú(ê«û¡òõ)
  • plasma lipoproteins
    Ç÷Àå(úìíì) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد)
  • plasma proteins
    Ç÷Àå ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • plasma sol
    Á¹»ó(ßÓ) ¿øÇüÁú(ê«û¡òõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ISA Instrument Society of America; intracarotid sodium amytal; intrinsic simulating activity; intrinsic ...
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
LP labile peptide; labile protein; laboratory procedure; lactic peroxidase; lamina propria; laryngophar...
L/P lactate/pyruvate [ratio]; liver plasma [concentration]; lymph/plasma [ratio]
PC avoirdupois weight [Lat. pondus civile]; packed cells; paper chromatography; paracortex; parent cell...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
D/P Dialysate-to-plasma ratio
D/P Dialysate/plasma
ERPF Effective Renal Plasma Flow
FPG Fasting plasma glucose
FPI Fasting plasma insulin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma substitute
    Ç÷Àå ´ë¿ëÁ¦
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • pooled plasma
    È¥ÁÖ Ç÷Àå
  • renal plasma flow
    ½Å Ç÷Àå·ù, ½Å Ç÷Àå·ù·®
  • venous plasma blood glucose
    Á¤¸Æ Ç÷Àå Ç÷´çÄ¡, Á¤¸Æ Ç÷Àå Ç÷´ç
  • activity
    Ȱ¼ºµµ, Ȱµ¿µµ
    1. Ȱ¼ºÈ­µÈ »óÅÂ. ¾î¶² È¿°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â ´É·Â. ¾î¶² ÀÛ¿ë ¶Ç´Â ±â´ÉÀÇ ¿¬Àå. 2. ºñÀÌ»óÀûÀÎ ¿ë¾×¿¡¼­ È¿°úÀûÀÎ ³óµµ¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Â ¿­¿ªÇÐÀûÀÎ ¾ç. ¸¸¾à ³óµµ°¡ Ȱµ¿µµ·Î ´ëü µÈ´Ù¸é ÆòÇü»ó¼ö¿¡ °üÇÑ ¹æÁ¤½Ä, ÀüÀ§, »ïÅõ¾Ð, ²ú´Â Á¡ ¿À¸§, ¾î´Â Á¡ ³»¸², Èֹ߼º ¿ëÁúÀÇ Áõ±â¾ÐÀº Èñ¼® ¿ë¾×¿¡¼­ ¸ðµç ³óµµ¿¡ ´ëÇØ °íÁ¤µÈ Á¤È®ÇÑ ¹æÁ¤½ÄÀÇ ±Ù»ç °ªÀ¸·Î ¹Ù²î¾î Áø´Ù. Ȱµ¿µµ´Â ºñÀÌ»óÀûÀÎ °ÍÀ¸·ÎºÎÅÍ ÃøÁ¤µÈ ºÎÇǰ¡ ¾ø´Â ¼ýÀÚ, Ȱµ¿°è¼ö¿Í »ý»ê¹°ÀÇ ³óµµ¿Í °°´Ù.
  • activity index
    Ȱµ¿ Áö¼ö
  • antibacterial activity
    Ç×±Õ ÀÛ¿ë
  • binding activity
    °áÇÕ È°¼º
  • bone activity
    °ñ Ȱ¼º
  • chemotactic activity
    È­ÇÐ ÁÖ¼º´É
  • concomitant activity
    µ¿¹Ý Ȱµ¿, ºÎ¼öÀû È¿°ú
  • diurnal activity
    ÁÖ°£ ÀÌ»ó ±â´É Ȱµ¿
  • efferent activity
    ¿ø½É Ȱ¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
structure-activity relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
drug activity A measure of the physiological response a drug produces. A less active drug produces less response (and visa versa).
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
intrinsic sympathomimetic activity The property of a drug that causes activation of adrenergic receptors so as to produce effects similar to stimulation of the sympathetic nervous system.
(05 Mar 2000)
optical activity The ability of a material to rotate the plane of polarized light.
(09 Oct 1997)
triggered activity One or a series of spontaneously generated heart beats originating from an action potential that produces an after-depolarisation which reaches activation threshold.
(05 Mar 2000)
unit of thyrotrophic activity The activity of an amount of an extract of the anterior lobe of the hypophysis which, given daily for 5 days, will cause the thyroid of a guinea pig (weighing 200 g) to reach a weight of 600 mg.
(05 Mar 2000)
zone of polarizing activity <cell biology> The small group of mesenchyme cells in avian limb buds that is located at the posterior margin of the developing bud and that produces a substance, possibly retinoic acid, that provides positional information to the developing limb bud.
(18 Nov 1997)
antihemophilic plasma Human plasma in which the labile antihemophilic globulin component, present in fresh plasma, has been preserved; it is used to temporarily relieve dysfunction of the haemostatic mechanism in haemophilia.
(05 Mar 2000)
apical plasma membrane <cell biology> The term used for the cell membrane on the apical (inner or upper) surface of transporting epithelial cells.
This region of the cell membrane is separated, in vertebrates, from the baso lateral membrane by a ring of tight junctions that prevents free mixing of membrane proteins from these two domains.
(18 Nov 1997)
basolateral plasma membrane <cell biology> The plasma membrane of epithelial cells that is adjacent to the basal lamina or the adjoining cells of the sheet. Differs both in protein and phospholipid composition from the apical plasma membrane from which it is isolated by tight junctions (zonula occludentes).
(18 Nov 1997)
beam-plasma reaction <radiobiology> Fusion reaction which occurs from the collision of a fast beam ion with a thermal plasma ion.
(09 Oct 1997)
bean-shaped plasma <radiobiology> A toroidal plasma indented on the inboard side (the side with the donut hole), that results in additional stability to ballooning modes. Moderate indentation may provide access to the second-stability region (high beta).
(13 Nov 1997)
blood plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á